The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients With Heart Failure

摘要: Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, costs associated with recurrent hospitalizations advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, transplantation, place a substantial financial burden on health care system. The present criteria for risk stratification patients are inadequate often prevent allocation appropriate treatment. Patients who have received ICDs primary prevention sudden death receive no device therapy their lifetime, whereas other dysfunction die suddenly without meeting ICD implantation.